NeuroSense Therapeutics Ltd. Operating Cash Flow
NeuroSense Therapeutics Ltd. (NRSN) reported Operating Cash Flow of -$7.67 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-03-31
| Period end | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|
| 2025-12-31 | -$7.67M 20-F · filed 2026-03-31 | |
| 2025-06-30 | -$4.00M 6-K · filed 2025-08-01 | |
| 2024-12-31 | -$10.13M 20-F · filed 2026-03-31 | |
| 2024-06-30 | -$5.75M 6-K · filed 2025-08-01 | |
| 2023-12-31 | -$8.35M 20-F · filed 2026-03-31 | |
| 2023-06-30 | -$3.90M 6-K · filed 2024-09-30 | |
| 2022-12-31 | -$7.62M 20-F · filed 2025-04-07 | |
| 2021-12-31 | -$1.54M 6-K · filed 2024-06-17 |